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Abstract
Background: The aim of the present study is to compare the early and mid-term clinical and hemodynamic results of
the aortic valve replacement (AVR) with a St Jude Medical Regent 19-mm prosthesis (SJMR-19) versus Carpentied-Edwars
bovine pericardial 19-mm valve (CE-19).
Methods: Between January 2002 and January 2012, 265 patients (Group I) and 58 patients (Group II) with underwent
AVR with a SJMR-19 and CE-19 respectively. There were no significant differences between groups regarding
the demographic and preoperative echocardiographic data. Thirty-six patients in Group I and 4 in Group II
required annulus enlargement in association or not with septal myectomy. The mean follow-up was 34 ± 18.5 months
(range 5–60 months).
Results: There were 14 (5.3 %) hospital deaths in Group I versus 4 (6.8 %) in Group II (p = 0.86). The multivariate logistic
regression analysis identified the LVEF ≤ 35 % (p = 0.001), combined operation (p = 0.0005), CPB (p = 0.033), age
(p = 0.011), annulus enlargement (p = 0.0009), reoperation (p = 0.039) and chronic renal failure (p = 0.011) as
strong predictors for early postoperative death. Within 1 year after surgery peak pulmonary artery pressure,
interventricular septal and left ventricular posterior wall thickness decreased significantly in both groups. The
M-TPG was 15.7 ± 6.5 mmHg in Group I versus 17 ± 7 mmHg in Group II (p = 0.19). The multivariate regression
analysis revealed the annulus enlargement (p = 0.018), small EOAi (p = 0.00004), postoperative LVMi (p = 0.0001)
and BSA (p = 0.019) as strong predictors for higher M-TPG. The postoperative LVMi was 119 ± 22.5 gm/m
2 in
Group I and 122 ± 22 gm/m2 in Group II (p = 0.37), significantly lower than the respective preoperative values 162.5 ± 34
gm/m2 (Group I) and 168 ± 30 gm/m2 (Group II). The actuarial survival and cumulative free-reoperation actuarial survival
at 5 years follow-up were 96.7 and 94.5 % respectively in Group I and 97 and 91 % in Group II.. There were non significant
differences between groups regarding the actuarial survival and cumulative free-reoperation survival. The Cox model
identified the older age (p = 0.022), LVEF≤ 35 % (p = 0.009), reoperation (p = 0.018), combined surgery (p = 0.00075) and
annulus enlargement (p = 0.033) as strong predictors for poor actuarial free-reoperation survival.
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Conclusions: Both the SJMR-19 and CE-19 offers excellent postoperative clinical and hemodynamic outcome in patients
with small aortic annulus. The LV hypertrophy and transvalvular gradients are reduced significantly indenpendently of the
employed SJMR-19 or CE-19 prosthesis. Our data support recent suggestions that small valve size does not influence
intermediate free-reoperation survival. The CE-19 is an excellent alternative to SJMR-19 in old patients.
Keywords: St Jude Medical Regent 19-mm mechanical aortic prothesis, Carpentier-Edwards bioprothesis, Indexed
effective orficice area, Indexed left ventricular mass
Background
Aortic valve replacement (AVR) in patients with a small
aortic annulus is often challenging for the surgeon in
terms of prosthesis selection. The goal of surgery is to
replace the valve with a competent, nonstenotic pros-
thesis that allows resolution of patient symptoms and
normalization of hemodynamics. Although it is easy to
define a competent prosthesis, defining what constitutes
a nonstenotic prosthesis has been a challenge. AVR with
a small prosthetic valve is technically straightforward
and commonly performed, but it may result in a patient-
prosthetic mismatch resulting in a high residual outflow
gradient, the significance of which remains the subject
of controversy [1–8]. Annular enlargement allows for in-
sertion of a larger aortic prosthesis, but it too may intro-
duce increased surgical risks [9]. Use of stentless valves
or homografts results in lower residual postoperative
gradients, but implant procedures are technically
more demanding, leading to increased total ischemic
time [10, 11] and the log-term durability remain un-
known [11, 12]. The Carpentier-Edwards (CE) pericar-
dial valve, a stented tissue valve made of bovine
pericardium, is widely used in patients with small aor-
tic roots. Rao et al. [10] provided evidence that stent-
less and stented valves have similar hemodynamic
profiles in the small aortic root when matched on
true measured internal diameters demonstrating that
the clinical benefit of the stentless porcine valve may
be due to patient selection or the lack of a rigid stent in
the small aortic root, but it is not due to hemodynamic su-
periority over stented aortic valves of similar sizes.
Bileaflet mechanical valves are still the most implanted
cardiac valve substitutes in the aortic position. Their excel-
lent durability and low incidence of cardiac-related compli-
cations have been widely reported [3, 13]. The St. Jude
Medical Regent 19-mm mechanical aortic prosthesis
(SJMR-19) valve is the next-generation bileaflet mechanical
prosthetic aortic valve, constructed of pyrolytic carbon
which has a modified external profile that achieves a larger
geometric orifice area without changing the existing design
of the pivot mechanism or blood-contact surface areas.
The aim of the present study is to report the early and
mid-term clinical and hemodynamic results of the AVR
with a SJMR-19 versus CE-19.
Methods
Between January 2002 and January 2012, 265 patients
(Group I) and 58 patients (Group II) with aortic valve
disease underwent AVR with a SJMR-19 and CE-19
respectively. Valve replacement was performed for
rheumatic, congenital or degenerative valve disease and
severe aortic valve stenosis with or without regurgitation.
The investigational board (The IRB of the division
of cardiac surgery at the University Hospital Center of
Tirana, Albania, the scientific committee of the division
of cardiac surgery of Bergamo, Italy, and the IRB of
the division of experimental surgery, cardiac surgery
section, University of Florence, Italy) approved the study
protocol as a multi-institutional study and written in-
formed consent was obtained from all patients. The
prosthesis type was basically decided by the surgeons’
preference in selected cases, patients’ decision regarding
the long-term anticoagulation and older age.
Patients’ characteristics
Preoperative demographic data are given in Table 1.
Mean age was 67.5 ± 12.72 years in Group I and 71 ±
16 years in Group II (p = 0.07). Almost 102 patients from
Group I were older than 65 years. In this subset of pa-
tients a mechanical valve SJMR-19 was employed due to
technical difficulties of employing a biological valve be-
cause of the very small aortic annulus. In some other
cases was the patient’s preference or not availability of
the CE-19. The age, weight and BSA distribution for all
patients are given in Fig. 1a-c. Preoperative echocardio-
graphic data are given in Table 2. There were no signifi-
cant differences between groups regarding the
demographic and preoperative data.
Anaesthesia and cardiopulmonary bypass
The inducement of anaesthesia consisted in: Fentanyl
(25–30 γ/Kg), Diazepam (0,2 mg/Kg) and Bromure of
Pancuronium (0,1 mg/Kg), and maintained with Rami-
fentanil (1–3 γ/Kg/min), Propofol and Isofluorane if ne-
cessary. The right atrium was cannulated using a double
stage cannula. Normothermia and intermittent antero-
grade warm blood cardioplegia was employed. The left
ventricle was vented through the right superior pul-
monary vein.
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Operative techniques
The aortic annulus was debrided meticulously and
measured with a snugly fitting sizer. Prosthesis size was
selected according to the size of the aortic annulus. The
AVR with a larger size aortic prosthesis such as 21-mm
valves was tempted in all cases. AVR prosthesis size and
type (Carpentier-Edwards bovine pericardial or SJMR
were left to the discretion of the operating surgeon. We
rim the annulus with interrupted 2–0 Ethibond (Ethicon,
Somerville, NJ) mattress sutures, with or without Teflon
(Impra Inc, a subsidiary of L.R. Bard, Tempe, AZ)
pledgets. The prosthesis were inplanted in the supraan-
nular position in all cases. Thirty-six patients in Group I
and 4 in Group II required annulus enlargement in asso-
ciation or not with septal myectomy. We enlarge the
aortic annulus by extending the standard oblique aortot-
omy down through the commissure between the left and
noncoronary sinuses, about 1 to 1.5 cm into the base of
the anterior mitral leaflet and a long elliptical Hemashild
patch was employed to enlarge the left ventricular
outflow tract and to close the entire aortotomy. The op-
erative and early postoperative data are given in Table 3.
Anticoagulation
All patients in Group I were anticoagulated with
warfarin sodium from the second postoperative day. All
patients in Group II continued the anticoagulation ther-
apy for three months after surgery. The international
normalized ratio was used as control and kept between
2.5 and 3.5.
Follow-up
The mean follow-up was 35 ± 18.5 months (range 13–87
months). The INR, clinical status for any cardiac event
were evaluated. Prior discharge all patients underwent
echocardiographic examination. The second postopera-
tive echocardiographic control was performed within
1 year after surgery. The mean time-interval between
the echocardiographic examination and the operation
was 17 ± 5 months. Further follow-up was based on
medical records of patients’ medical visits, following
echocardiographic examinations (not all of them) and by
telephone contacts.
Echocardiography
Studies were performed with the use of 2.5–3.5 MHz
transducer interfaced to SONOS 5500 (Agilent Tech-
nologies, Andover, Mass). All patients were monitored
with serial echocardiograms; the first study was
performed preoperatively, subsequent controls were at
discharge and within 1 year postoperatively. Images were
stored on tape for late off-line analysis. M-mode, twodi-
mensional, continuous pulsed-wave, and color Doppler
were carried out and standard views were used. Mea-
surements of end-systolic diameter (ESD), end-diastolic
diameter (EDD), posterior wall thickness (WT), and in-
terventricular septal thickness (IVST) were first made
according to the recommendation of the American
Society of Echocardiography using a leading edge-to-
leading edge convention. Left ventricular ejection
fraction (LVEF) was calculated by using the apical
four-chamber view and the application of the modi-
fied Simpson rule method.
Table 1 Demographic data
Variables Group I Group II p
(n = 265) (n = 58)
Males 1 (19.3 %) 14 (24 %) 0.51
Mean age (years) 67.5 ± 12.72 71 ± 16 0.07
Mean Canadian Cardiovascular Class 1.41 ± 0.62 1.34 ± 0.63 0.44
Mean New York Heart Association class 2.4 ± 0.75 2.34 ± 0.82 0.6
Mean height (cm) 159.7 ± 7.7 161.8 ± 12 0.1
Mean weight (kg) 66.2 ± 12.7 67 ± 13 0.67
Mean Body Surface Area (m2) 1.67 ± 0.14 1.69 ± 0.25 0.41
Mean Body mass Index (kg/m2) 26 ± 4.8 25.5 ± 4.4 0.47
Aortic stenosis 223 (84 %) 48 (82.7 %) 0.95
Diabetes 35 (13.2 %) 6 (10.4 %) 0.71
Insulin therapy 7 (2.7 %) 1 (1.7 %) 0.95
Hypercholesterolemia 82 (31 %) 16 (27.6 %) 0.87
Hypertension 118 (44.5 %) 21 (36 %) 0.31
Hypothyroidism 15 (5.7 %) 1 (1.7 %) 0.36
Smoking history 61 (23 %) 10 (17.3 %) 0.43
Chronic renal failure 11 (4.2 %) 6 (10.4 %) 0.11
Cerebrovascular disease 4 (1.5 %) 3 (5.2 %) 0.22
Previous transitory ischemic arrest 17 (6.4 %) 6 (10.4 %) 0.44
Previous carotid endarterectomy 7(2.7 %) 0 0.45
Previous peptic ulcer 21 (8 %) 5 (8.6 %) 0.93
Peripheric vascular disease 11 (4.2 %) 2 (3.5 %) 0.90
Preoperative arrhythmias 24 (9 %) 5 (8.6 %) 0.88
Permanent pacemaker 7 (2.7 %) 2 (3.5 %) 0.92
Nonelective 10 (3.8 %) 6 (10.4 %) 0.08
Endocarditis 11 (4.2 %) 4 (7 %) 0.58
Reoperation 31 (11.7 %) 4 (7 %) 0.41
III-IV reoperation 7 (2.7 %) 0 0.45
Ischemic heart disease 37 (14 %) 7 (12 %) 0.86
Myocardial Infarction 12 (4.5 %) 3 (5.2 %) 0.89
Chronic obstructive pulmonary Disease 31 (11.7 %) 8 (13.8 %) 0.83
Congestive heart failure 44 (16.6 %) 9 (15.5 %) 0.9
Left Ventricular Ejection Fraction≤ 35 % 33 (12.5 %) 6 (10.4 %) 0.82
Mean Euroscore 6.9 ± 2 7.1 ± 2.9 0.51
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Doppler measurements and calculations
The maximal instantaneous pressure gradient across the
prostheses was estimated by the modified Bernoulli
equation; the mean pressure gradient was derived by
planimetry of the Doppler envelope. Patient-prosthesis
missmatch was defined as those patients with EOAi
below 0.75 cm2/m2 and the severe patient prothesis
mismatch was considered when the EOAi was below the
10th percentile (≤0.65 cm2/m2) [6].
Definitions
Body surfacearea (BSA) is body morphometric analysis
indexing weights and heights. Indexed left ventricular
mass reduction (R- LVMi) is the difference between the
preoperative value of the LVMi and postoperative LVMi.
Statistical analysis
Group statistics were expressed as mean ± SD. The
generalized Wilcoxon test was performed for the statis-
tical analysis between groups. Fisher’s exact test was
used for the non continuous variables. The relationship
between preoperative and postoperative variables within
the same group was assessed by the McNemar test. The
multivariate logistic regression model was employed to
determine the predictors for poor early survival. The
multivariate Cox proportional regression (Statsoft 6–0)
was performed to determine independent predictors.
Long-term survival rates were calculated using the
Kaplan-Meier method and the long rank test for the
comparison between groups. The Spearman linear re-
gression test was employed for analysing the correlation
between variables. Significance between data was con-
sidered achieved when p < 0.05.
Results
There were 14 (5.3 %) hospital deaths in Group I versus
4(6.8 %) in Group II (p = 0.86). The postoperative com-
plications and causes of early deaths are given in Table 3.
There were no differences between groups regarding the
postoperative complications. The multivariate logistic re-
gression analysis identified the LVEF ≤ 35 %, combined
operation, CPB, age, annulus enlargement, reoperation
Fig. 1 Distribution of a age; b weight and c body surface area
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and chronic renal failure as strong predictors for early
postoperative death (Table 4).
All survivors underwent echocardiographic examin-
ation at discharge. The mean transprosthesis gradient
was 19 ± 9 mmHg in Group I versus 20 ± 5 mmHg in
Group II (p = 0.2). At six months follow-up the mean
NYHA FC class was 1.6 ± 0.5 in Group I and 1.8 ± 0.7 in
Group II (p = 0.014). However the NYHA FC improved
significantly in both groups versus the preoperative
values. All survivors underwent transthoracic echocardi-
ography examination at rest within 1 year after surgery
(Table 5). Peak pulmonary artery pressure decreased sig-
nificantly after surgery, (p = 0.001 and p = 0.002 in Group
I and II respectively. The end-diastolic IVS thickness de-
creased significantly after AVR, (p = 0.001 and p = 0.012 in
Group I and II respectively). The end-diastolic LV poster-
ior wall thickness decreased significantly only in Group I
(p = 0.035). On the other hand the end-systolic pos-
terior wall thickness decreased significantly in both
groups after AVR, (p = 0.012 and p = 0.026 in Group I
and II respectively).
The M-TPG was 15.7 ± 6.5 mmHg in Group I ver-
sus 17 ± 7 mmHg in Group II (p = 0.19), however the
M-TPG was significantly lower than preoperatively in-
dependently of the employed prosthesis (Fig. 2a). The
mean transprosthesis gradient was significantly lower
than at discharge in Group I (p = 0.003) and Group II
(p = 0.011). The multivariate regression analysis revealed
the annulus enlargement, small EOAi, increased LVEDD,
postoperative LVMi, BSA and older age as strong predic-
tors for higher M-TPG (Table 6).
LVM and LVMi were significantly lower than pre-
operatively independently of the employed prosthesis
(Table 5) (Fig. 2b). The R-LVMi was similar between
Table 2 Preoperative echocardiographic data between groups
Variables Group I Group II p-value
(n = 251) (n = 54)
Diameter of the ascending aorta (mm) 29.3 ± 4.8 28.8 ± 5.3 0.5
Diameter of the left atrium (mm) 47 ± 10.5 45 ± 5 0.17
End-diastolic right ventricle diameter (mm) 22.3 ± 7.2 22.7 ± 6.8 0.71
End-diastolic LV diameter (mm) 48 ± 7.2 47.8 ± 7.6 0.86
End-systolic LV diameter (mm) 27.3 ± 7.6 28.3 ± 6.3 0.37
End-diastolic IVS thickness (mm) 13.3 ± 2.5 13.5 ± 3 0.61
End-systolic IVS thickness (mm) 17.8 ± 3.5 18 ± 5.4 0.73
End-diastolic LV PW thickness (mm) 11.2 ± 1.7 11.6 ± 2.5 0.16
End-systolic LV PW thickness (mm) 17.5 ± 3.5 17.7 ± 3.8 0.71
Shortening Fraction (%) 43.17 ± 8.6 45 ± 11 0.18
End-diastolic LV volume (ml) 101.5 ± 34.2 105 ± 31 0.49
End-systolic LV volume (ml) 44.2 ± 25 46 ± 20 0.62
Indexed end-diastolic LV volume (ml/mq) 60.4 ± 20 62 ± 23 0.61
Indexed end-systolic LV volume (ml/mq) 26.6 ± 15 27 ± 11 9.85
Left ventricular ejection fraction (%) 56.8 ± 12.6 54 ± 17 0.17
VmaxE (cm/s) 112 ± 58 120 ± 52 0.35
VmaxA (cm/s) 124 ± 41.5 132 ± 39 0.2
Mitral valve regurgitation grade 2.13 ± 0.8 1.97 ± 0.9 0.19
Peak pulmonary artery pressure (mmHg) 49.3 ± 14.7a 48 ± 12a 0.55
Left ventricular mass (gm) 271 ± 58 285 ± 60 0.11
Left ventricular mass index (gm/m2) 162.5 ± 34 168 ± 30 0.27
Peak transvalvular gradient (mmHg) 102.4 ± 24 108 ± 23 0.12
Mean transvalvular gradient (mmHg) 61 ± 16 60 ± 10 0.66
Aortic valve regurgitation grade 2.1 ± 0.8 2 ± 0.6 0.39
Peak trans tricuspid valve gradient 39.6 ± 12 37.5 ± 14 0.26
R/spess 2.13 ± 0.5 2.2 ± 0.7 0.39
R/spessmed 2.16 ± 1.16 2 ± 1.1 0.35
LV left ventricle, IVS Interventricular septum, PW posterior wall
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groups (Table 5). The M-TPG had a strong direct correl-
ation with the postoperative LVMi (Fig. 3a) and an indir-
ect correlation was found with the postoperative EOAi
(Fig. 3b) independently of the employed SJMR-19 or
CE-19. Also the LVMi correlated well with the EOAi
independently of the prosthesis type (Fig. 3c).
Table 3 Intraoperative and early postoperative data
Variables Group I (%) Group II (%) p-value
Mean cardiopulmonary bypass time (minutes) 104 ± 41 98 ± 53 0.34
Mean aortic cross-clamping time (minutes) 82 ± 32 78 ± 37 0.41
Annulus enlargement 36 (13.6 %) 4 (6.9 %) 0.24
Mitral valve replacement 31 (11.7 %) 4 (6.9 %) 0.41
Coronary artery bypass grafting 37 (14 %) 7 (12 %) 0.87
Total grafts 66 (25 %) 12 (20.7 %)
Associated carotid endarterectomy 4 (1.5 %) 0 0.78
Tricuspid valve repair 8 (3 %) 4 (6.9 %) 0.30
Postoperative outcome
Mean mechanical ventilation (hours) 9.8 ± 9.5 12.3 ± 14 0.10
Mean Intensive Care Unit stay (days) 3 ± 6.4 2.7 ± 2.6 0.73
Readmitted in Intensive Care Unit 8 (3 %) 3 (5.2 %) 0.68
Postoperative complications 52 (19.6 %) 14 (24 %) 0.55
Low cardiac output 39 (14.7 %) 9 (15.5 %) 0.96
Myocardial infarction 10 (3.8 %) 2 (3.5 %) 0.79
Ventricular arrhythmias 27 (10 %) 5 (8.6 %) 0.91
Heart Block 4 (1.5 %) 1 (1.7 %) 0.64
Reoperation for bleeding 15 (5.7 %) 3 (5.2 %) 0.87
Blood used 126 (47.6 %) 30 (52 %) 0.67
Pulmonary complications 17 (6.4 %) 5(8.6 %) 0.75
ARDS 3 (1.1 %) 1 (1.7 %) 0.78
Pneumonia 9 (3.4 %) 2 (3.5 %) 0.71
Reintubation 12 (4.5 %) 3 (5.2 %) 0.90
Neurological complications 9 (3.4 %) 0.33
Stroke 2 (0.75 %) 0 0.80
Infectious complications 14 (5.3 %) 4 (6.9 %) 0.87
Septicemia 5 (2 %) 1 (1.7 %) 0.65
Deep sternal wound infection 4 (1.5 %) 2 (3.5 %) 0.64
Superficial sternal wound infection 5 (2 %) 1 (1.7 %) 0.65
Renal complications 19 (7.2 %) 9 (15.5 %) 0.08
Hemodialysis 7 (2.6 %) 3 (5.2 %) 0.56
Multi organ failure 5 (2 %) 1 (1.7 %) 0.65
Coagulopathy 5 (2 %) 1 (1.7 %) 0.65
Hospital death 14 (5.3 %) 4 (6.9 %) 0.87
Hospital death in reoperated patients 6 (2.3 %) 2 (3.5 %) 0.22
Causes of hospital death
Cardiac 8 (3 %) 3 (5.2 %) 1.0
Septicemia 1 (0.4 %) 0 1.0
Intestinal infarction 1 (0.4 %) 0 1.0
Multi organ failure 3 (1.1 %) 1 (1.7 %) 1.0
Aortic dissection 1(0.4 %) 0 1.0
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The actuarial survival and cumulative free-reoperation
actuarial survival at 5 years follow-up were 96.7 % and
94.5 % respectively in Group I and 97 % and 91 % in
Group II (Fig. 4a and b). There were non significant
differences between groups regarding the actuarial
survival and cumulative free-reoperation survival. The
actuarial free-reoperation survival was significantly lower
in patients with LVEF < 35 % (Fig. 4c), undergoing com-
bined surgery (Fig. 4d), in patients older than 75 years
(Fig. 5a), although the M-PTG ≥ 20 mmHg, EOAi ≤
0.75 cm2/m2 and LVMi ≥ 130gm/m
2 did not decrease the
cumulative actuarial free-reoperation survival (Fig. 5b-d).
Other minor complications were identified in seven pa-
tients as listed in Table 7.
We constructed a model including all and adverse
events. The Cox model identified age ≥ 75 years, LVEF ≤
35 %, chronic renal failure, NYHA FC class ≥ 3, reopera-
tion, combined surgery, and annulus enlargement as
strong predictors for poor actuarial free-major events
survival (Table 8).
Discussion
Management of the small aortic root is a challenge to
the surgeon with regard to operative technique and
selection of prosthesis. Many techniques have been
described [9] to accommodate a larger prosthesis, poten-
tially increasing the risks of injury to the coronary arter-
ies and conduction bundle, and of surgical hemorrhage.
On the other hand the stented bioprothesis such as
the CE-19 remains an alternative to mechanical
prosthesis, homografts, stentless valves and annulus
enlargement techniques.
The mechanical prosthesis still remain the most widely
use prosthesis for AVR basically due to their proven
long-durability, less technical difficulties and costs. The
employment of mechanical prosthesis in small aortic
annulus is still an issue of controversies in the literature,
however, most of surgeons confirm excellent prosthesis
hemodynamic in patients undergoing AVR with a small
mechanical prosthesis. The SJMR heart valve features a
modified outer profile as compared to the standard SJM
mechanical heart valve carbon orifice. This modification
allows for an increase in the inside lumen area while
maintaining the same tissue annulus diameter and sew-
ing cuff diameter as a SJM mechanical heart valve HP
valve or a SJM standard mechanical heart valve.
In the present study we report a large series of 265
patients undergoing AVR with a SJMR-19. The early and
mid-term clinical and hemodynamic outcome were
compared with a group of patients undergoing AVR with a
CE-19. The early postoperative outcome in patients with a
SJMR-19 were similar to other reported series [14–16].
Similar outcome were found in patients undergoing AVR
with a CE-19 [10, 17–21]. The assessment of clinical out-
comes relies on long-term assessment for years and de-
cades. However, within the available follow-up of just more
than 35 months, there were excellent clinical outcomes
among patients independently of the valve type regarding
Table 4 Predictors for hospital death and adverse events after aortic valve replacement
Err.Std. Err.Std.
BETA di BETA B di B t (265) p-level
Predictors for early postoperative mortality
LVEF≤ 35 % −0.31 0.07 −0.21 0.05 −4.52 0.00012
Combined operation −0.32 0.07 −0.29 0.06 −4.7 0.00005
Annulus enlargement −0.28 0.069 −0.16 0.04 −4.02 0.0009
CPB 0.12 0.057 0.069 0.032 2.15 0.033
Age −0.16 0.061 −0.003 0.0012 −2.58 0.011
Reoperation 0.13 0.06 0.08 0.04 2.07 0.039
Chronic renal failure −0.15 0.06 −0.17 0.065 −2.58 0.011
Predictors for early postoperative adverse events
LVEF≤ 35 % −0.27 0.073 −0.33 0.092 −3.63 0.0004
CPB 0.27 0.069 0.008 0.0021 3.87 0.0002
Combined operation −0.22 0.071 −0.17 0.042 −3.1 0.0031
Annulus enlargement −0.25 0.086 −0.18 0.062 −3.0 0.0041
Residual gradient −0.172 0.087 −0.007 0.0033 −1.98 0.049
Chronic renal failure −016 0.074 −0.155 0. −2.15 0.033
Reoperation −0.17 0.073 −0.14 0.06 −2.31 0.022
Endocarditis 0.14 0.07 0.092 0.05 1.99 0.048
LVEF left ventricular ejection fraction, CPB cardiopulmonary bypass time
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to the improvement of the functional status assessed by
New York Heart Association, and there were acceptable ad-
verse events in terms of embolic, bleeding and endocarditis.
The basal transprothesis peak and mean gradients
were similar to other series of patients undergoing AVR
with SJM standard mechanical prosthesis or SJMHP
[5, 22]. Bach et al. [14] reported a significantly lower
M-TPG of 9.7 mmHg in 22 patients undergoing AVR
with SJMR-19 from a series of 361 patients undergo-
ing AVR with SJMR compared to our series of
patients, this probably due to the fact that the mean
EOA in this study [14] was 1.6 ± 0.4 cm2, higher than
our series. In a previous study, the same authors [23]
had found a M-TPG of 13.8 mmHg in patients undergo-
ing AVR with SJMR-19. By the other side Gelsomino et
al.[15] found a M-TPG of 17 mmHg at 1 year after AVR
with SJMR-19 in patients representing a postoperative
EOAi = 0.82 cm
2/m2 slightly higher than our series. In an-
other study Sudkamp et al.[16] found a P-TPG of almost
26 mmHg in patients with an EOA of 1.38 cm2 undergoing
AVR with a SJMR-19. The M-TPG in patients undergoing
AVR with a SJMR-19 was lower, eventhough not significant
than CE-19. Other studies have demonstrated controversial
data regarding the M-TPG in patients with CE-19. The M-
Table 5 Postoperative echocardiographic data between groups
Variables Group I Group II p-value
Diameter of the ascending aorta (mm) 30 ± 4.2 31.2 ± 7 0.1
Diameter of the left atrium (mm) 45.4 ± 9.4 44.5 ± 7 0.51
End-diastolic right ventricle diameter (mm) 22 ± 8 23 ± 6 0.39
End-diastolic LV diameter (mm) 46.6 ± 6 47 ± 9 0.69
End-systolic LV diameter (mm) 28 ± 6.7 28.6 ± 6 0.55
End-diastolic IVS thickness (mm) 12 ± 1.6a 12.2 ± 2.3a 0.45
End-systolic IVS thickness (mm) 17.4 ± 5 17.6 ± 4.6 0.79
End-diastolic LV PW thickness (mm) 11.5 ± 1.5a 11.3 ± 2.7 0.45
End-systolic LV PW thickness (mm) 16.4 ± 6a 16 ± 4a 0.86
Shortening Fraction (%) 40.5 ± 9.8 43 ± 11 0.1
End-diastolic LV volume (ml) 85 ± 28.7 91 ± 27 0.16
End-systolic LV volume (ml) 37.5 ± 18.3 40 ± 17 0.36
Indexed end-diastolic LV volume (ml/mq) 50 ± 15 53 ± 17 0.2
Indexed end-systolic LV volume (ml/mq) 21.7 ± 9.7 23.4 ± 11 0.26
Left ventricular ejection fraction (%) 56.4 ± 10.7 55 ± 12 0.4
VmaxE (cm/s) 126 ± 44 122 ± 37 0.54
VmaxA(cm/s) 118.4 ± 29.5 123 ± 33 0.31
Mitral valve regurgitation grade 1.64 ± 0.53a 1.5 ± 0.8a 0.11
Peak pulmonary artery pressure (mmHg) 43 ± 12.8a 40 ± 14a 0.13
Left ventricular mass (gm) 199 ± 38a 207 ± 61a 0.22
Left ventricular mass index (gm/m2) 119 ± 22.5a 122 ± 22a 0.37
Left ventricular mass index reduction (gm/m2) 44.1 ± 30 46.4 ± 26 0.60
Peak transvalvular gradient (mmHg) 28.3 ± 11a 31 ± 12a 0.11
Mean transvalvular gradient (mmHg) 15.7 ± 6.5a 17 ± 7a 0.19
Aortic valve regurgitation grade 1.1 ± 0.3 1.2 ± 0.9 0.15
Peak trans tricuspid valve gradient 34 ± 11.4 32 ± 13 0.26
Effective orifice area 1.35 ± 0.14 1.33 ± 0.2 0.38
Indexed effective orifice area (cm2/m2) 0.81 ± 0.12 0.79 ± 0.1 0.26
Indexed orifice area < 0.75 cm2/m2 110 (43.8 %) 24 (44.4 %) 0.95
Indexed orifice area≤ 0.65 cm2/m2 19 (7.5 %) 3 (5.6 %) 0.82
Doppler Velocity Index 0.5 ± 0.15 0.48 ± 0.2 0.41
Mitral valve area (cm2) 3.7 ± 6.3 3.5 ± 4.2 0.83
aThe postoperative value is significantly lower than preoperatively
LV left ventricle, IVS interventricular septum, PW posterior wall
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TPG for CE-19 range between 12 and 24 mmHg and the
EOA between 1.1 cm2 and 1.4 cm2 [10, 17–21]. In our
series we found a 17 mmHg and an EOA of 1.32 cm2.
The hemodynamic performance of currently available
AV prostheses remains inferior to those of the native
AV. All current prosthetic valve designs produce
measurable TPG that, potentially, could place persistent
additional demands on the LV, and may hinder or delay
the regression of LV hypertrophy. This is said to occur
more frequently when the size of the implanted pros-
thesis is limited by the presence of a small aortic annu-
lus, particularly in a patient with a large BSA, when
Fig. 2 a. Postoperative M-TPG versus preoperative value in both groups. b. Comparison between the preoperative and postoperative values of
the LVMi
Table 6 Predictors for high mean transprothesis gradients
Err.Std. Err.Std.
BETA di BETA B di B t (265) p-level
LVMi (gm/m2) 0.4 0.05 7.84 0.97 8.07 0.00000
EOAi (cm2/m2) −0.21 0.050210 −0.14 0.033 −4,18 0.00004
LVEDD (mm) 0.097 0.05 −2.33 1.2 −1.95 0.053
Annulus enlargement 0.13 0.054 2.46 1.03 2.4 0.018
Body surface area (m2) 0.13 0.052 0.068 0.03 2.35 0.019
Age (years) 0.12 0.055 1.69 0.77 2.18 0.03
EOAi aortic indexed effective orifice area, LVEDD left ventricular end-diastolic diameter, LVMi indexed left ventricular mass
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there is a mismatch between prosthesis and patient?!
Persistently elevated LVM in these patients, as a result
of a small prosthesis with obstructive gradients, may in-
crease the risk of sudden death [8]. The presence of LV
hypertrophy in old patients such as the present series
with a high incidence of concomitant CABG and at a
higher risk of developing severe coronary artery disease
postoperatively increases the risk for late deaths [24].
Persistently high postoperative gradients are thought to
impair the regression of LVM observed in most patients
after surgery [1, 25]. Complete abolition of transvalvular
gradients is not possible because of the obstructive
effects of the prosthetic valve stents and sewing ring.
Although the reduction in LVMi seen in our patients
was significant independently of the employed prosthesis
type, it should be noted that the average postoperative
LVMi remained above the normal range. A similar
observation has been made in another study noting a
significant regression of LVM with small mechanical
valves [26], but observed persistent elevations in mass
compared with controls, which were due to persistent
septal thickening. There are several possible reasons for
incomplete regression of AV stenosis patients may
preclude complete regression of LV hypertrophy. It is
also possible that although significant regression of LVM
had occurred, it may be a continuing process and further
reductions of LVM might occur at 2 and 3 years postop-
eratively. Another possibility is that the AV procedure
itself resulted in an increase in LVM that partially offset
the benefits of the lower aortic gradient. Thoracotomy
itself may increase the LVM [27]. The postoperative
LVM and LVMi in our series were significantly lower
than preoperatively, indicating that both the implanted
SJMR-19 and CE-19 had reduced significantly the pres-
sure gradient across the AV. It may well be argued that
during the follow-up, favourable LV remodelling as a
result of sustained relief of outflow obstruction has
occurred inducing a near normalisation of systolic load
Fig. 3 a. Correlation between LVMi and M-TPG. Correlation between EOAi and the b M-TPG, c Postoperative LVMi in both groups
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following AV replacement associated with a rapid rate of
reduction in myocyte hypertrophy and LVM. This was
demonstrated even by a significant reduction of the IVS
thickness and posterior LV wall hypertrophy in our
series independently of the employed prosthesis. These
data confirm that both SJMR-19 and CE-19 offers
acceptable transprothesis gradients at rest, which are
compatible with an almost normal systolic load of the
LV. Previous studies, performed in patients receiving
19-mm mechanical prothesis or bioprothesis showed
similar results at follow-up [13, 20, 22]. A strong direct
correlation between the M-TPG and postoperative
LVMi was found both in patients with SJMR-19 and
CE-19, as already demonstrated in other series under-
going AVR with larger size mechanical prothesis, how-
ever the opinions regarding such correlation remains
still controversial [11]. We also found a strong inverse
correlation between the M-TPG and EOAi in patients
with SJMR-19 and CE-19, similarly to other reported
studies [5, 28]. Furthermore, the EOAi inversely corre-
lated with the postoperative LVMi. Such data clearly
demonstrate the strong effect of the small EOAi on the
increased postoperative LVMi, independently of the
employed prosthesis type.
Patient-prosthesis mismatch has been accepted on
the basis of assumptions, indirect evidence, and intui-
tive reasoning. The postoperative EOAi in our study
was similar between SJMR-19 and CE-19 and the mean
value was ≤0.85 cm2/m2 in both groups demonstrating
patient-prosthesis missmatch. Patient-prosthesis mismatch
has mostly been defined by the presence of abnormal gra-
dients in a setting of decreased EOAi. Although most of
authors have found the patient-prosthesis missmatch a
strong predictor for higher postoperative TPG and late
survival the opinions are still controversial [3–8, 29]. For
patients with AV stenosis, there is a widely accepted cor-
relation between the reduction of transvalvular gradients
and clinical improvement after AVR [1]. Recent studies
Fig. 4 a The actuarial survival and b cumulative free-reoperation actuarial survival in both groups. The cumulative free-major events actuarial
survival in patients with LVEF < 35 % (c) and in patients undergoing combined surgery (d)
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[2, 4, 5] have demonstrated that patient-prothesis mis-
match does not adversely impact on long-term survival,
and that valve size may be unimportant. Eventhough
we were not able to demostrate in our series the
adverse effect of the small EOAi on overall free-
reoperation survival, our analysis demonstrated a sig-
nificant impact of the small EOAi on the postoperative
M-TPG. Almost 110 from 251 survivors with SJMR-19
and 24 out of 54 survivors with CE-19 had an EOAi ≤
0.75 cm2/m2 which demonstrates a patient-prosthesis mis-
match according to definitions given by Rao et al.[8], but
very few of them had an EOAi ≤ 0.65 cm2/m2 according to
the new definition given by Goldman et al. [5]. Although
the patient-prosthesis mismatch was frequently found in
our series independently of the employed prosthesis type,
we may hypothetize that the low incidence of severe
patient-prothesis mismatch as demonstrated by our data,
may have hider and overlaped the real impact of the small
EOAi on mid-term free-reoperation survival. Although
patient-prosthesis mismatch remains a constant concern
in prosthesis’ selection, especially in patients with small
aortic root, AVR with the SJMR-19 or CE-19 pericardial
bioprosthesis offers excellent midterm results and remains
a valuable alternative to aortic root enlargement tech-
niques and to small stentless valves in the elderly.
Other variables such as older age, low LVEF, presence
of chronic renal failure, combined surgery associated
annulus enlargement and the presence of M-TPG ≥
20 mmHg were strong predictors for poor overall free-
reoperation survival. Sawant et al. [3] in a series of 593
patients undergoing AVR with a SJM 19-mm found the
older age as an important predictor for poor survival
although the concomitant surgical procedure did not
influence long-term survival. He and colleagues [29]
reported that the small prosthesis with concomitant
CABG was the only negative determinant of long-term
survival. In another study [30] the age and heart-related
variables were independent risk factors for mortality,
thromboembolism, bleeding, serious complications, and
all complications joined. Carrier et al. [19] found the
Fig. 5 The actuarial free reoperation survival (a) in patients older than 75 years, (b) in patients with postoperative M-TPG > 20 mmHg, (c) in patients
with EOAi < 75 and (d) in patients with LVMi ≥ 130gm/m2(N)
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older age, male sex, associated CABG and aortoplasty as
independent predictors for poor overall free-events
survival in a series of 93 patients undergoing AVR with
CE-19. The concomitant annulus enlargement was
another predictor for poor overall free-events survival in
our series confirming other surgical series undergoing
annulus enlargement techniques [9] which demonstrated
relative success, but at the expense of increased opera-
tive risk. In our practice, the indication for annulus
enlargement was given in cases when the implantation
of a SJMR-19 or CE-19 was not possible in the aortic na-
tive annulus. However, the other alternative in such
occasions is to implant a smaller valve such as a SJMR-
17-mm. During the same study period, we have
implanted a SJMR-17 in 17 patients and the initial out-
come are encouraging [31, 32]. The annulus enlarge-
ment was an independent predictors for poor actuarial
overall free-reoperation survival.
The principal concern of the mechanical valve is its
thrombogenic potential and the need for anticoagula-
tion. In this series there was no incidence of valve
thrombosis. The review by Akins [33] of four com-
mon mechanical prosthesis revealed a linearized rate
of thromboembolism at 1.6 % patient-years (range, 0.7
Table 7 Causes of late deaths and adverse events




Cardiac arrest 2 (1 in Group II) No
Valve related






Endocarditis 4 (1 in Group II) 2 Yes
Myocardial ischemia 2 Yes
Important paravalvular leak 2 (1 in Group II) Yes
Aortic dissection 1 Yes
Important mitral valve regurgitation 1 (Group II) Yes
Minor adverse events
aRenal insufficiency requiring hemodialysis 1 No
Reversible ischemic neurologic deficit 3 No
Moderate paravalvular leak 3 No
Gastric hemorrhage 1 Yes
aThe same patients requiring reoperation due to endocarditis
Table 8 Predictors for overall free-reoperation survival
Errore Esponenz Statist.
Beta Standard Valore t beta di Wald p-value
NYHA FC ≥3 −0.39 0.20 −1.91 0.68 3.66 0.056
Age (years) −0.67 0.29 −2.3 0.51 5.3 0.022
LVEF≤ 35 % 0.65 0.25 −2.61 0.53 6.83 0.009
Chronic renal failure −0.63 0.33 −1.96 0.53 3.83 0.050
Reoperation 0.52 0.22 2.37 1.7 5.63 0.018
Combined surgery 1.02 0.30 3.37 2.78 11.36 0.00075
Annulus enlargement 0.026 0.012 2.13 1.03 4.55 0.033
LVEF left ventricular ejection fraction, NYHA FC New Yourk Heart Association Functional Class
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to 2.8 %) for the SJM prosthesis. Our findings con-
firm the durability and minimum thrombogenicity of
the SJMR prostheses.
The actuarial survival and overall free-reoperation
survival were similar in patients with SJMR-19 versus
CE-19. Although almot 40 % of patients underwent
concomitant cardiac procedures, in this series the opera-
tive mortality and the intermediate survivals were similar
with other reported series [3, 13, 14, 29, 32]. The late
survival and cumulative free-reoperation survival were
strongly related with the older age, combined operation
and low LVEF. Eventhough this study demonstrate simi-
lar hemodynamic performance between the SJMR-19
and CE-19, the long-term durability of the CE-19 is
much more lower than the mechanical prosthesis due to
proven structural valve failure. For this reason, in our
practice, we have indicated the employement of the
CE-19 only in elderly patients.
Study limitations
1) One of the major limitations of the continuous–wave
Doppler is the possibility of overestimation of valvular
flow velocity and pressure gradients and underestima-
tion of the valve area by the continuity equation, as a
consequence of pressure-recovery phenomenon. 2)
Another limitation is the older age of patients under-
going AVR with a SJMR-19 or CE-19. These patients
have reduced daily physical activities and as conse-
quence might be “false” assymptomatic. 3) The pa-
tients in this study were not homogeneous and were
included patients undergoing double valve replace-
ment or coronary artery bypass grafting, although the
loading conditions on a prosthetic valve should be
similar in all patient subgroups.
Conclusion
We may conclude that the SJMR-19 and CE-19 offers
acceptable postoperative clinical and hemodynamic
outcome in patients with small aortic annulus. The LV
hypertrophy and transvalvular gradients are reduced
significantly, independently of the employed prosthesis
type. Our data demonstrates that small valve size
(19 mm) of St Jude Regent and Carpentier Edwards are
associated with acceptable mid-term free-reoperation
survival. The hemodynamic results of CE-19 mm are
similar to SJMR-19 in old patients.
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